{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:50:55Z","timestamp":1794081055687,"version":"4.8.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.annonc.2021.07.006","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T04:02:43Z","timestamp":1626926563000},"page":"1348-1365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1055,"title":["Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606"],"prefix":"10.1016","volume":"32","author":[{"given":"A.","family":"Gronchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Miah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"Dei Tos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Abecassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bielack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bonvalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Boukovinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.M.G.","family":"Bovee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brodowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Buonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"De \u00c1lava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.G.","family":"Del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fedenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ferraresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Frezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gasperoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Grignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hecker-Nolting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jungels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kopeckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Kr\u00e1korov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Le Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Legius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Leithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lopez-Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Martin-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Merimsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Messiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Morland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Palmerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Piana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sangalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sbaraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Scheipl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sundby Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Trama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Unk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.J.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.T.A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"van Houdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Frebourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.G.","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.07.006_bib1","series-title":"Soft Tissue and Bone Tumours. 3","year":"2020"},{"key":"10.1016\/j.annonc.2021.07.006_bib2","unstructured":"Casali PG, Blay JY, Abecassis N, et\u00a0al. Gastrointestinal stromal tumours: ESMO\u2013EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021."},{"key":"10.1016\/j.annonc.2021.07.006_bib3","unstructured":"Strauss SJ, Frezza AM, Gronchi A, et\u00a0al. Bone sarcomas: ESMO\u2013EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021."},{"issue":"8","key":"10.1016\/j.annonc.2021.07.006_bib4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet \u2013 a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.07.006_bib5","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/annonc\/mdx484","article-title":"Improved survival using specialized multidisciplinary board in sarcoma patients","volume":"28","author":"Blay","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.07.006_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.critrevonc.2016.12.002","article-title":"ECCO essential requirements for quality cancer care: soft tissue sarcoma in adults and bone sarcoma. A critical review","volume":"110","author":"Andritsch","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.annonc.2021.07.006_bib7","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1093\/annonc\/mdr610","article-title":"Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions","volume":"23","author":"Ray-Coquard","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.07.006_bib8","series-title":"Soft Tissue Sarcoma Histopathology Reporting Guide Resection Specimens","author":"Dei Tos","year":"2021"},{"issue":"1","key":"10.1016\/j.annonc.2021.07.006_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijc.2910330108","article-title":"Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system","volume":"33","author":"Trojani","year":"1984","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2021.07.006_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2015.09.021","article-title":"Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting","volume":"53","author":"Wardelmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.07.006_bib11","series-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2016"},{"issue":"5","key":"10.1016\/j.annonc.2021.07.006_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","article-title":"Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis","volume":"17","author":"Callegaro","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2021.07.006_bib13","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.2012.44.3747","article-title":"Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets","volume":"31","author":"Gronchi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.07.006_bib14","doi-asserted-by":"crossref","first-page":"100215","DOI":"10.1016\/j.eclinm.2019.11.008","article-title":"Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors","volume":"17","author":"Callegaro","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.annonc.2021.07.006_bib15","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.annonc.2021.07.006_bib16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00000658-198209000-00009","article-title":"The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy","volume":"196","author":"Rosenberg","year":"1982","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.annonc.2021.07.006_bib17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1996.14.3.859","article-title":"Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma","volume":"14","author":"Pisters","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.07.006_bib18","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1245\/s10434-014-3732-4","article-title":"Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial","volume":"21","author":"Beane","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.07.006_bib19","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1245\/s10434-018-6393-x","article-title":"Adequate local control in high-risk soft tissue sarcoma of the extremity treated with surgery alone at a reference centre: should radiotherapy still be a standard?","volume":"25","author":"Fiore","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.07.006_bib20","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1002\/cncr.26489","article-title":"The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity","volume":"118","author":"Dagan","year":"2012","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2021.07.006_bib21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.2017.74.6941","article-title":"Analysis of margin classification systems for assessing the risk of local recurrence after soft tissue sarcoma resection","volume":"36","author":"Gundle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9325","key":"10.1016\/j.annonc.2021.07.006_bib22","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial","volume":"359","author":"O'Sullivan","year":"2002","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.annonc.2021.07.006_bib23","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2015.62.9394","volume":"33","author":"Palassini","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.07.006_bib24","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1158\/1078-0432.CCR-19-3524","article-title":"A\u00a0phase II trial of 5-day neoadjuvant radiotherapy for patients with high-risk primary soft tissue sarcoma","volume":"26","author":"Kalbasi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.07.006_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2018.09.028","article-title":"Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres","volume":"105","author":"Callegaro","year":"2018","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.annonc.2021.07.006_bib26","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1002\/cncr.32911","article-title":"Extrameningeal solitary fibrous tumors-surgery alone or surgery plus perioperative radiotherapy: a retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet","volume":"126","author":"Haas","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2021.07.006_bib27","doi-asserted-by":"crossref","first-page":"e205865","DOI":"10.1001\/jamaoncol.2020.5865","article-title":"Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial","volume":"7","author":"Lansu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.07.006_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jamaoncol.2017.4996","article-title":"Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial","volume":"4","author":"Issels","year":"2018","journal-title":"JAMA Oncol"},{"issue":"30","key":"10.1016\/j.annonc.2021.07.006_bib29","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1200\/JCO.2011.35.6618","article-title":"Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas","volume":"29","author":"Deroose","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.07.006_bib30","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","article-title":"Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial","volume":"19","author":"Frustaci","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2021.07.006_bib31","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2021.07.006_bib32","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) sarcoma groups","volume":"38","author":"Gronchi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.07.006_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2018.12.009","article-title":"The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial","volume":"109","author":"Pasquali","year":"2019","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.annonc.2021.07.006_bib34","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/annonc\/mdw430","article-title":"Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group","volume":"27","author":"Gronchi","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.07.006_bib35","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.athoracsur.2009.04.144","article-title":"Resection of pulmonary and\u00a0extrapulmonary sarcomatous metastases is associated with long-term survival","volume":"88","author":"Blackmon","year":"2009","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"10.1016\/j.annonc.2021.07.006_bib36","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1200\/JCO.1993.11.7.1276","article-title":"An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas","volume":"11","author":"Antman","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.07.006_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.07.006_bib38","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"D'Ambrosio","year":"2020","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.annonc.2021.07.006_bib39","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1158\/1078-0432.CCR-13-0776","article-title":"Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics","volume":"19","author":"Stacchiotti","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2021.07.006_bib40","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.annonc.2021.07.006_bib41","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.07.006_bib42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.07.006_bib43","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ejso.2017.03.011","article-title":"Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate \u2013 the impact of fibrosarcomatous transformation","volume":"43","author":"Rutkowski","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.07.006_bib44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2021.07.006_bib45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.07.006_bib46","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.annonc.2020.08.2232","article-title":"Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network","volume":"31","author":"Demetri","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2021.07.006_bib47","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.1995.13.7.1600","article-title":"High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas","volume":"13","author":"Le Cesne","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.07.006_bib48","doi-asserted-by":"crossref","first-page":"868973","DOI":"10.1155\/2013\/868973","article-title":"Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma","volume":"2013","author":"Martin-Liberal","year":"2013","journal-title":"Sarcoma"},{"issue":"8","key":"10.1016\/j.annonc.2021.07.006_bib49","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.07.006_bib50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaoncol.2019.6584","article-title":"Assessment of safety and efficacy of combined trabectedin and low-dose radiotherapy for patients with metastatic soft-tissue sarcomas: a nonrandomized phase 1\/2 clinical trial","volume":"6","author":"Martin-Broto","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9829","key":"10.1016\/j.annonc.2021.07.006_bib51","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic\u00a0soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.annonc.2021.07.006_bib52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","article-title":"Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial","volume":"20","author":"Martin-Broto","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.07.006_bib53","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S1470-2045(19)30319-5","article-title":"Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial","volume":"20","author":"Stacchiotti","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10028","key":"10.1016\/j.annonc.2021.07.006_bib54","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Schoffski","year":"2016","journal-title":"Lancet"},{"issue":"30","key":"10.1016\/j.annonc.2021.07.006_bib55","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2016.71.6605","article-title":"Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine","volume":"35","author":"Demetri","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2021.07.006_bib56","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.07.006_bib57","doi-asserted-by":"crossref","first-page":"e180219","DOI":"10.1001\/jamaoncol.2018.0219","article-title":"Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: a multi-institutional case series","volume":"4","author":"Frezza","year":"2018","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.annonc.2021.07.006_bib58","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study","volume":"29","author":"Garcia-Del-Muro","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.07.006_bib59","doi-asserted-by":"crossref","first-page":"e1777","DOI":"10.1634\/theoncologist.2020-0352","article-title":"The activity of chemotherapy in inflammatory myofibroblastic tumors: a multicenter, European retrospective case series analysis","volume":"25","author":"Baldi","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.annonc.2021.07.006_bib60","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1038\/bjc.2014.200","article-title":"What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients","volume":"110","author":"Rothermundt","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2021.07.006_bib61","doi-asserted-by":"crossref","unstructured":"Swallow CJ, Strauss DC, Bonvalot S, et al. Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group. Ann Surg Oncol. 2021. https:\/\/doi.org\/10.1245\/s10434-021-09654-z.","DOI":"10.1245\/s10434-021-09654-z"},{"issue":"9","key":"10.1016\/j.annonc.2021.07.006_bib62","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1245\/s10434-012-2342-2","article-title":"Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG","volume":"19","author":"Bonvalot","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.07.006_bib63","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdr323","article-title":"Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas","volume":"23","author":"Gronchi","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.07.006_bib64","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/SLA.0000000000000978","article-title":"Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study","volume":"260","author":"Angele","year":"2014","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.annonc.2021.07.006_bib65","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy\u00a0plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.07.006_bib66","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1245\/s10434-016-5336-7","article-title":"Management of recurrent retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group","volume":"23","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.07.006_bib67","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jama.2014.1093","article-title":"Evaluating the risks of electric uterine morcellation","volume":"311","author":"Kho","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.annonc.2021.07.006_bib68","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpobgyn.2011.07.003","article-title":"Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential","volume":"25","author":"Ip","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.annonc.2021.07.006_bib69","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ygyno.2020.04.001","article-title":"Effect of bilateral salpingo-oophorectomy on the overall survival of premenopausal patients with stage I low-grade endometrial stromal sarcoma; a National Cancer Database analysis","volume":"157","author":"Nasioudis","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.07.006_bib70","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2021.07.006_bib71","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.27942","article-title":"Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)","volume":"119","author":"Hensley","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2021.07.006_bib72","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1073\/pnas.1115528109","article-title":"14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma","volume":"109","author":"Lee","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annonc.2021.07.006_bib73","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2017.03.021","article-title":"YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy","volume":"145","author":"Hemming","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.07.006_bib74","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1097\/LGT.0b013e3182a22019","article-title":"Hormonal therapy for aggressive angiomyxoma: a case report and proposed management algorithm","volume":"18","author":"Schwartz","year":"2014","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.annonc.2021.07.006_bib75","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","article-title":"The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients","volume":"127","year":"2020","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.07.006_bib76","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/PPO.0000000000000254","article-title":"Long-term efficacy of methotrexate plus vinblastine\/vinorelbine in a large series of patients affected by desmoid-type fibromatosis","volume":"23","author":"Palassini","year":"2017","journal-title":"Cancer J"},{"issue":"7","key":"10.1016\/j.annonc.2021.07.006_bib77","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/pbc.24457","article-title":"Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study","volume":"60","author":"Skapek","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"10.1016\/j.annonc.2021.07.006_bib78","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.ejca.2009.08.016","article-title":"Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis","volume":"45","author":"Constantinidou","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2021.07.006_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CAD.0000000000000474","article-title":"Pazopanib, a promising option for the treatment of aggressive fibromatosis","volume":"28","author":"Szucs","year":"2017","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.annonc.2021.07.006_bib80","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2017.02.001","article-title":"Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG)","volume":"76","author":"Kasper","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.07.006_bib81","doi-asserted-by":"crossref","first-page":"S975","DOI":"10.1016\/j.annonc.2020.08.1850","article-title":"1624MO Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: a multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)","volume":"31","author":"Broto","year":"2020","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2021.07.006_bib82","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-20-1847","article-title":"Long-term outcomes of oral vinorelbine in advanced, progressive desmoid fibromatosis and Influence of CTNNB1 Mutational Status","volume":"26","author":"Mir","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.annonc.2021.07.006_bib83","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for advanced and refractory desmoid tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2021.07.006_bib84","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.07.006_bib85","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annonc.2021.07.006_bib86","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2018.10.024","article-title":"Activity of axitinib in progressive advanced solitary fibrous tumour: results from an exploratory, investigator-driven phase 2 clinical study","volume":"106","author":"Stacchiotti","year":"2019","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.annonc.2021.07.006_bib87","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1002\/cncr.26098","article-title":"Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor","volume":"117","author":"Park","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2021.07.006_bib88","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-2600(18)30116-4","volume":"6","author":"Schoffski","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.annonc.2021.07.006_bib89","doi-asserted-by":"crossref","first-page":"14551","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.annonc.2021.07.006_bib90","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2021.07.006_bib91","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/1078-0432.CCR-20-2819","article-title":"Activity and safety of geptanolimab (GB226) for patients with unresectable, recurrent, or metastatic alveolar soft part sarcoma: a phase II, single-arm study","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2021.07.006_bib92","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10197","key":"10.1016\/j.annonc.2021.07.006_bib93","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2021.07.006_bib94","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.07.006_bib95","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2019.12.001","article-title":"A\u00a0double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib","volume":"126","author":"Penel","year":"2020","journal-title":"Eur J Cancer"},{"issue":"15","key":"10.1016\/j.annonc.2021.07.006_bib96","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2021.07.006_bib97","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.33247","article-title":"Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: a case-series analysis within the Italian Rare Cancer Network","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.annonc.2021.07.006_bib98","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1158\/1078-0432.CCR-19-0288","article-title":"Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas)","volume":"25","author":"Sanfilippo","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.annonc.2021.07.006_bib99","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/cncr.28109","article-title":"Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF\/GETO)","volume":"119","author":"Chevreau","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.annonc.2021.07.006_bib100","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1093\/annonc\/mds143","article-title":"Sunitinib malate in solitary fibrous tumor (SFT)","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.07.006_bib101","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421021840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421021840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:06:51Z","timestamp":1760335611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421021840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0923753421021840"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.07.006","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}